{"analyses":[{"ciLowerLimit":"0.69","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.11","estimateComment":"A hazard ratio \\<1 favours Osimertinib 80 mg","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"<0.001","paramType":"Hazard Ratio (HR)","paramValue":"0.87","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"17.2","upperLimit":"23.2","value":"20.0"},{"groupId":"OG001","lowerLimit":"16.5","upperLimit":"22.0","value":"19.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"279"},{"groupId":"OG001","value":"140"}],"units":"Participants"}],"description":"Time from randomisation to second subsequent anti-cancer therapy (SST) following randomised treatment discontinuation, or death if no SST administered. Any patient not known to have died nor received any SST was censored at the last time known not to have received SST, ie, the last follow-up visit this was confirmed.","dispersionType":"95% Confidence Interval","groups":[{"description":"Daily single dose of Osimertinib 80mg","id":"OG000","title":"Osimertinib 80mg"},{"description":"Platinum-based doublet chemotherapy","id":"OG001","title":"Chemotherapy"}],"paramType":"MEDIAN","populationDescription":"Full Analysis set (All randomised patients)","reportingStatus":"POSTED","timeFrame":"From date of randomisation until time of final OS analysis, a median follow-up of 43 months","title":"Time to Second Subsequent Therapy (TSST)","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"Months"}